- Back
- Back
- Back
- Back
- Back
- Back
- Back
- Back
- Back
- Back
A keynote session at the BHTA Joint Section Meeting on 18 June 2026, at the British Motor Museum in Warwickshire, explored the latest developments across the UK Government’s MedTech agenda.
The session was presented by Paul Griffiths, Head of Policy and Strategy for Medical Technology & Innovation at the Department of Health and Social Care (DHSC).
Opening the session, Paul highlighted the arrival of new ministers, including James Murray, Secretary of State for Health and Social Care, and Preet Kaur Gill, Minister for Life Sciences and Innovation.
He said the key message from the new ministerial team was the continuation of existing direction and priorities.
Wave One of the new Part IX process is now underway, with applications having closed in March and assessments being carried out by independent advisory panels.
Paul noted that a review will take place following the first wave to assess how the process is working in practice and identify any unintended consequences before future waves are introduced.
He also highlighted the introduction of temporary listings for products that demonstrate strong potential but require additional real-world evidence before being considered for permanent inclusion. The provision allows products to be listed for up to two years while further evidence is generated.
Paul said several companies are already making use of the temporary listing route, which has been introduced to help innovative products reach patients sooner while supporting further evidence generation.
Members also received an update on the National HealthTech Access Programme, formerly known as the Rules-Based Pathway.
The programme aims to create a clearer route from regulatory approval through to evaluation, reimbursement, and NHS adoption. The first technologies have now entered the NICE Technology Appraisal process.
Paul said the programme is intended to make the NHS a more predictable customer for innovation, supporting both technology adoption and growth across the UK’s life sciences sector.
Following engagement with more than 300 SMEs and extensive work with NHS organisations, industry representatives, and other stakeholders, the government published guidance on value-based procurement for medical technology in June.
The approach has been tested through pilot projects at 13 NHS trusts, with an independent evaluation examining how the methodology performs in live procurement settings and what support organisations may need to implement it more widely.
Paul said the next phase will focus on training, implementation support, and adoption across NHS organisations.
Paul provided updates on Design for Life, the programme supporting the transition towards a more circular approach to MedTech.
Work is continuing on priority adoption programmes, with sustainability considerations being incorporated into wider decision-making processes.
Alongside this, he outlined progress on Project Phoenix, which is developing a clean room in HMP Ranby to test the concept of manufacturing MedTech in prisons.
Another programme highlighted during the session was MedTech Compass, a DHSC-led platform designed to help NHS organisations compare products using trusted evidence sources.
The platform will bring together information from NICE guidance, pilot evaluations, procurement exercises, and other datasets to support purchasing decisions. The programme entered beta development in June.
Paul also noted that Compass has been identified as the delivery vehicle for the Innovator Passport programme, helping to support more consistent adoption of technologies across the NHS.
The session concluded with an update on several areas of regulatory reform.
Paul highlighted progress on pre-market regulation changes, which are moving through the final stages of development. He also discussed ongoing work around international recognition and reliance pathways, following consultation with industry and other stakeholders.
Paul also highlighted forthcoming recommendations relating to AI as a medical device.
Members also heard about ongoing discussions regarding industry payments disclosure. A series of stakeholder workshops has been taking place to explore different options and gather views from industry, patient groups, and NHS organisations before decisions are taken on next steps.
BHTA members involved in NHS tenders are encouraged to take part in a Department of Health and Social Care (DHSC) industry readiness survey on value-based procurement (VBP).
This survey provides an opportunity for companies across the health technology sector to share their perspectives and help shape how VBP is implemented across the NHS in England.
Value-based procurement shifts the focus from reducing product costs to delivering better outcomes and lowering total costs across the patient pathway.
NHS Supply Chain is working with the NHS and industry to apply this approach in practice, aiming to improve efficiency, reduce waste, and deliver measurable benefits such as increased productivity, reduced infection rates, and improved patient outcomes.
The approach also supports closer collaboration between suppliers, procurement teams, and healthcare providers, with a focus on delivering long-term value to the health system.
More information on VBP can be found in this BHTA article.
DHSC has developed national VBP standard guidance, currently being piloted by 13 NHS Trusts, with publication expected in summer 2026.
The survey has been designed to assess industry readiness and understand organisational attitudes towards VBP. Findings will inform DHSC’s implementation plans and support the transition to value-based approaches across the NHS.
It asks organisations to provide:
Responses are confidential and will not be shared with third parties.
Relevant members are encouraged to submit a response before the deadline via the value-based procurement survey.
Members involved in NHS tenders or expecting to be impacted by changes to procurement frameworks are particularly encouraged to participate.
The NHS is strengthening its commitment to innovation and efficiency through the introduction of new value-based procurement (VBP) standards for medical technology.
The Department of Health and Social Care (DHSC) has published the ‘Value Based Procurement Standard Guidance for Medical Technology’, designed for use within the NHS’s 13 VBP pilots. Although the guidance has been created to support these pilot projects, it also provides valuable insights and practical applications for the wider medical technology sector.
The guidance is intended for use by both NHS buyers and suppliers to help assess not only the cost of medical devices but also the broader value they deliver to patients, staff, and the healthcare system.
This shift towards value-based decision-making comes alongside the government’s announcement that the NHS will invest in pioneering technology to help reduce waiting lists and improve productivity across services. Together, these initiatives aim to ensure that procurement decisions increasingly reward technologies that demonstrate measurable improvements in outcomes, efficiency, and sustainability.
The new DHSC guidance establishes a framework for evaluating medical devices across five domains: social value, efficiency, patient and staff outcomes, supply chain resilience, and purpose. A sixth factor, whole-life cost, complements these domains by ensuring that price is considered within the broader context of lifecycle value.
Under the new framework, NHS buyers are encouraged to assess tenders not solely on upfront cost but on the overall contribution a product or service makes to the health system.
Each domain can be weighted according to the needs of a particular procurement, but social value must account for at least 10 percent of the total weighting, in line with the NHS Social Value Playbook. Overall, at least 60 percent of procurement scoring must relate to the value domains, while whole-life cost is capped at 40 percent.
This marks a step away from purely price-driven procurement and towards a model that prioritises long-term outcomes, sustainability, and patient benefit.
Each of the five value domains provides a structured set of questions and evaluation criteria for buyers and suppliers. The social value domain encourages suppliers to demonstrate how they will reduce carbon emissions, manage modern slavery risks, or improve sustainability in packaging and disposal. The efficiency domain considers how a product can simplify patient pathways, increase hospital or community productivity, and support accurate measurement of outcomes. The patient and staff domain emphasises safety, patient experience, and health equity, while supply chain and purpose focus on resilience, interoperability, and ease of use.
Suppliers are expected to provide measurable, evidence-based responses that show how their technologies can deliver tangible improvements. This includes providing baseline data, real-world evidence, and models that quantify benefits such as reduced complications, improved patient satisfaction, or optimised workforce time.
The guidance is part of a wider shift within the NHS towards integrating innovation, sustainability, and productivity.
Andrew New, CEO of NHS Supply Chain, said: “Innovative technology has a vital role to play in delivering faster, simpler and more effective care for patients. Through this new approach, we can ensure that procurement not only secures the best value for money but also supports the NHS in achieving its long-term goals around efficiency, sustainability and patient outcomes.”
BHTA member companies supplying medical technology to the NHS will need to engage more deeply with buyers to demonstrate measurable value through data, evidence, and partnership. This includes clearly articulating how their products support clinical efficiency, improve patient experience, and align with NHS sustainability objectives.
The framework also highlights the importance of collaboration between suppliers, clinical teams, and procurement professionals. Bidders are encouraged to provide evidence that supports their claims, including quantitative data, modelling, and independent validation where possible.
The guidance advises buyers to ensure proportionality in their tender requirements to support the participation of small and medium-sized enterprises (SMEs) within the medtech sector.
Suppliers may wish to focus on areas such as:
By preparing evidence-rich submissions aligned to the five value domains, suppliers can better position themselves to succeed in NHS tenders under this new approach.
The VBP guidance underscores a wider movement within the healthcare system towards smarter, more sustainable procurement. As the NHS aims to make better use of technology to enhance care delivery, these frameworks are helping to ensure that procurement decisions reflect genuine long-term value.
Andrew added: “By focusing on value rather than volume, we are creating the conditions for innovation to thrive — enabling suppliers to bring forward solutions that improve outcomes for patients and deliver efficiencies for the NHS.”
At the recent joint British Healthcare Trades Association (BHTA) and AXREM conference, David Lawson, Director of Medical Technology and Innovation at the Department of Health and Social Care (DHSC), set out the evolving landscape for medical technology.
‘The Future of MedTech – Innovating for Tomorrow’ conference was held on 13 May 2025 at The Mercure, Northampton.
David’s presentation was the final part of a compelling conference talk titled ‘Big Picture: What is the Future Policy Landscape for Medtech?’. The previous speaker, Nata Zaman, discussed NHS England’s New Hospital Programme and what that means for medtech.
David reflected on the MedTech Strategy alongside and some of the upcoming and ongoing DHSC initiatives that are crucial to medtech businesses across the UK.
Despite the frequent changes in ministers and departmental structures over the past few years, the original challenges identified in the MedTech Strategy remain highly relevant: supply resilience, innovation adoption, data infrastructure, and markets.
With the NHS under significant pressure and few easy options to increase funding or expand the workforce, medtech is increasingly seen as a key lever for transformation. Innovation adoption is not just a priority for healthcare delivery; it’s also vital to the success of the broader Industrial Strategy, where life sciences remains one of the UK’s “crown jewels”.
Technology as a solution to transform healthcare will also likely be flagged in the upcoming 10-year health plan, David noted.
David highlighted the importance of value-based procurement as a mechanism to support consistent decision-making and better uptake of technology. He acknowledged the lack of standardisation currently affecting procurement: “We don’t today have any standard of how medical technology should be assessed… so we shouldn’t be surprised when we see huge variation”.
To address this, the DHSC has been co-developing a simplified methodology – described as a “ladybird guide to procurement” – that incorporates a 40/60 weighting in favour of quality over price. It includes domain-based question banks for local teams to select from, offering clarity for both buyers and suppliers. Shadow testing is already underway with eight procurement teams, and a national launch is planned for January 2026.
A major development currently in progress is the DHSC MedTech Compass, which is described as “a single source of information where there’s visibility of products within categories and information on the various attributes of those products”.
David acknowledged the challenges SMEs face in getting products in front of decision-makers across the country: “People may not be aware that actually you have a product because SMEs don’t have the resource to be able to go around the whole country to make everyone aware.”
The Compass aims to not only showcase available technologies but also introduce a ‘passporting’ function to reduce repetitive data submissions about the same technologies to NHS trusts. Having completed its discovery phase, the project is now entering its alpha design stage this summer, with beta testing expected in 2026.
Crucial to both the Compass and the wider ambition for smarter regulation and procurement is a Product Information Management (PIM) system. As David noted: “We don’t have a single version of truth in terms of medical devices.” Poor data quality is hampering post-market surveillance regulatory requirements and innovation uptake.
The PIM is now entering its beta build phase. A private beta involving industry and health partners will follow shortly, ahead of a full public launch in January 2026. David stressed that the PIM will underpin future initiatives, including a more “risk-proportionate” regulatory approach from MHRA.
On the topic of the Part IX Drug Tariff, David acknowledged its complexity: “I describe Part IX like an onion. You peel a layer, and then suddenly another layer appears”. After extensive work to modernise categories and introduce logical groupings, a new scoring framework will be implemented this month.
A new temporary listing process will allow products with emerging evidence to be included on the tariff while further data is collected. David also flagged future work on local formularies, noting the lack of national guidance and the inconsistent practices this leads to: “There are certain parts of the country that [suppliers] don’t bother engaging with because of the approach that they take”.
A forthcoming report from National Voices, drawing on input from over 650 patients, will help ensure future categorisation and procurement processes better reflect patient priorities and lived experiences.
At ‘The Future of MedTech – Innovating for Tomorrow’ conference, Alexandra Hammond, Associate Director for Net Zero & Sustainable Procurement at NHS England, delivered the second part of a talk titled ‘Building a Sustainable Future through Responsible Procurement’.
Hosted by the British Healthcare Trades Association (BHTA) and AXREM, the conference took place on 13 May 2025 at The Mercure, Northampton.
The first part of the talk was delivered by Chris Taylor, Sustainability Lead UKI at Philips Health Systems.
Alexandra provided an in-depth look at how NHS England is embedding sustainability, social value, and modern slavery prevention into its procurement practices, all in support of the NHS’ broader net zero ambitions.
Alexandra began by highlighting that 66 percent of the NHS’ carbon footprint lies within its supply chain, positioning sustainable procurement as a powerful tool in the journey towards net zero. Her team’s mandate focuses on sustainable procurement and supply chains, while also driving social value and tackling modern slavery.
She reminded attendees of the NHS’ clear commitment: by the end of this decade, it will no longer work with suppliers who are not aligned with its net zero goals. To support this, the NHS Net Zero Supplier Roadmap lays out a series of milestones, several of which are already in place. These include embedding social value in all procurements and requiring suppliers to provide a carbon reduction plan.
From 2027, suppliers will be expected to expand the scope of their carbon reporting, with additional requirements on product-level emissions and disclosure coming in 2028. Alexandra emphasised that these future milestones are still in development and urged suppliers to take part in shaping the final policies.
A key enabler of the NHS’ sustainability work, Alexandra noted, is the National Procurement Policy Statement, published on 13 February 2025. This policy reinforces NHS England’s commitment to embedding net zero, social value, and ethical standards in procurement. Importantly, it aligns with wider government priorities for the public sector, including building an NHS for the future, kickstarting economic growth, and making the UK a clean energy superpower.
Alexandra explained that the statement is more than just guidance – it provides a formal basis for public sector organisations, including NHS bodies, to adopt procurement practices that reflect environmental and social priorities. It marks a shift from policy aspiration to concrete expectation.
Alexandra reassured suppliers that NHS England will take a proportionate, clear, and collaborative approach, with plenty of notice before implementing new policies. She noted that NHS England is listening closely to supplier feedback.
She also pointed to the NHS Evergreen Sustainable Supplier Assessment, hosted within the NHS Atamis e-procurement system, as a key tool for dialogue between the NHS and suppliers on sustainability. This tiered assessment enables suppliers to track and improve their maturity level on sustainability issues, without duplicating information across multiple systems.
Beyond net zero, Alexandra spoke about the evolving expectations around social value. The government’s updated procurement priorities now include building a future-ready NHS, alongside themes such as clean energy, economic growth, and inclusion.
New regulations on modern slavery are also on the horizon, with NHS England working closely with the Department of Health and Social Care to ensure that supply chains are fair, ethical, and transparent. Procurement will play a central role in embedding these requirements across the health system.
For BHTA members, Alexandra’s message was one of opportunity and urgency. The NHS is committed to supporting suppliers, including SMEs, with tools, guidance, and access to events and on-demand resources such as emissions verification webinars and updates on science-based targets.
Alexandra concluded with a strong call to action for suppliers: engage with the NHS on these changes, make use of the Evergreen tool, and help co-design the future of sustainable procurement.
At the recent British Healthcare Trades Association (BHTA) Conference 2024, David Lawson, Director of MedTech for the Department of Health and Social Care (DHSC), presented an engaging presentation on value-based procurement and a MedTech Strategy update.
The BHTA Conference 2024 focused on the UK healthtech landscape over the next five years. It was a chance for BHTA members to hear from senior government and NHS speakers about how the changes made today will impact the future of the health service.
In his presentation, David remarked that it is a very active time in the procurement and medtech sectors, and that there is a genuine desire for DHSC to engage with industry, including BHTA members, to ensure its proposals are grounded and well thought-out.
David reflected on the ‘The medical technology strategy: one year on’ report, which reflects on the MedTech Strategy and provides an update on where the medtech sector is headed. Since the MedTech Strategy was published, there are multiple medtech initiatives in flight, such as the Innovative Devices Access Pathway (IDAP).
One of the central themes in David’s discussion was around value-based procurement. He stressed that the lowest price does not always equal best value.
He also highlighted some of the key problems DHSC is trying to solve in the medtech sector. See the slide below.
One issue David particularly emphasised with evaluating procurement is around validating evidence submitted by suppliers.
He said: “Can we believe the claims from industry? How do we validate that? How do we trust the information? Having good data is part of that validation process.
“At the moment, there’s an absence of clarity in terms of validation. That leads to a lack of consistency. Different trusts across the country apply value-based procurement assessment of medtech in different ways. There isn’t a methodology to set a common way of doing this. That makes it inefficient for everyone.
“It’s quite difficult to do validation on medtech, because medtech doesn’t stand still. A product is developed, it then gets iterated, more data is collected, and more evidence is collected. It’s quite hard to make a validation process that’s dynamic and that reflects the way that medtech operates, alongside the scope and scale of medtech.”
David underlined that it may take a while for DHSC to come up with an appropriate, robust, and sustainable process for validating medtech.
In addition, David outlined potential options to move work forward. See the slide below.
David said: “This question about validation of evidence, our thinking at the moment is that we need a system solution. We need some sort of portal where suppliers can submit their information, there’s a validation process, and it can be updated.”
Moreover, David underlined some of the key issues DHSC is trying to iron out to make the medtech sector work more seamlessly. See the slide below.
“From a UK perspective, the majority of our medtech industry is SME-based, so we need to make sure that at a government level and a system level that we are doing everything we can to support SMEs, not make it harder,” he commented.